AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27959607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1766
Study 25381593 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior foraminotomy
Number of subjects: 88
Study 25381593 — intervention group
Group type: COMPARATOR
Intervention: Anterior foraminotomy with fusion
Number of subjects: 88
Study 25381593 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Outcome Measures Index
Number of subjects: 88
Study 25381593 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form-12 (SF-12) questionnaire
Number of subjects: 88
Study 25381593 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological outcomes
Number of subjects: 88
Study 25381593 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic outcomes
Number of subjects: 88
Study 23158721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative monitoring of oculomotor nerve during surgery
Number of subjects: 61
Study 23158721 — intervention group
Group type: COMPARATOR
Intervention: Microsurgery without intraoperative monitoring
Number of subjects: 61
Study 19279975 — intervention group
Group type: EXPERIMENTAL
Intervention: silver amalgam without zinc
Number of subjects: 50
Study 19279975 — intervention group
Group type: EXPERIMENTAL
Intervention: white MTA‐Angelus
Number of subjects: 50
Study 19279975 — intervention group
Group type: EXPERIMENTAL
Intervention: white Portland cement (PC)
Number of subjects: 50
Study 19279975 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 50
Study 19279975 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Fuji Ortho LC
Number of subjects: 50
Study 17978866 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary back pain prevention program
Number of subjects: 0
Study 17978866 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive model including change variables
Number of subjects: 0
Study 15890545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic foot and calf compression (IPC) for 3 hours per day for 6 months
Number of subjects: 34
Study 15890545 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise for three hourly sessions per week for 6 months
Number of subjects: 34
Study 15890545 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised exercise
Number of subjects: 34
Study 11927519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (300 microg/min for 15 minutes)
Number of subjects: 20
Study 11927519 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary saline
Number of subjects: 20
Study 10710774 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-timing tasks (self-paced and externally paced Sensorimotor Synchronization and Sensorimotor Anticipation)
Number of subjects: 11
Study 10710774 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-discrimination task
Number of subjects: 11
Study 7725882 — intervention group
Group type: EXPERIMENTAL
Intervention: HE azeotrope
Number of subjects: 33
Study 7725882 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia (H)
Number of subjects: 33
Study 7725882 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia with tetracaine (S)
Number of subjects: 33
Study 7725882 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HE, H, S)
Number of subjects: 33
Study 2209240 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese traditional medicine Xiao Chai Hu Tang (XCHT)
Number of subjects: 86
Study 2209240 — intervention group
Group type: EXPERIMENTAL
Intervention: biphenyl dimethyl dicarboxylate (BDD)
Number of subjects: 86
Study 2209240 — intervention group
Group type: EXPERIMENTAL
Intervention: XCHT + BDD
Number of subjects: 86
Study 2209240 — intervention group
Group type: COMPARATOR
Intervention: Control group (without treatment)
Number of subjects: 86
Study 7003449 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 200mg daily
Number of subjects: 30
Study 7003449 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 750mg daily
Number of subjects: 30
Study 31108488 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPULS treatment group
Number of subjects: 80
Study 31108488 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 28535549 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg (2 mL)
Number of subjects: 120
Study 28535549 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg (1 mL)
Number of subjects: 120
Study 28535549 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 mL) (Control group)
Number of subjects: 120
Study 25886789 — intervention group
Group type: EXPERIMENTAL
Intervention: SR‐WBV 5 Hz, Noise 4/SR‐WBV 1 Hz, Noise 1
Number of subjects: 20
Study 25886789 — intervention group
Group type: COMPARATOR
Intervention: SR‐WBV 1 Hz, Noise 1/SR‐WBV 5 Hz, Noise 1
Number of subjects: 20
Study 24004237 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B (6,000 U/kg IV)
Number of subjects: 14
Study 24004237 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% NaCl solution)
Number of subjects: 14
Study 21461451 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy sessions three times a week for 60 minutes
Number of subjects: 94
Study 21461451 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no music therapy)
Number of subjects: 94
Study 19477397 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP assay and echocardiography
Number of subjects: 1012
Study 19477397 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP assay
Number of subjects: 1012
Study 17077439 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 18
Study 17077439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10827375 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin plus aspirin
Number of subjects: 3171
Study 10827375 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus aspirin
Number of subjects: 3171
Study 8892117 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority Academic Advising Program (MAAP)
Number of subjects: 114
Study 8892117 — intervention group
Group type: COMPARATOR
Intervention: Control group (predominantly white nursing students)
Number of subjects: 114
Study 2067506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine sublingual 10 mg
Number of subjects: 36
Study 2067506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms.kg‐1 i.v.
Number of subjects: 36
Study 2067506 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 36
Study 6193349 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine once daily
Number of subjects: 20
Study 6193349 — intervention group
Group type: COMPARATOR
Intervention: Clonidine thrice daily
Number of subjects: 20
Study 31565244 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 274
Study 31565244 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg (dose escalated to 150 mg)
Number of subjects: 274
Study 29355055 — intervention group
Group type: EXPERIMENTAL
Intervention: Various recruitment methods (trial registration, posters/flyers, print publications, Internet, social media, radio, databases, referrals)
Number of subjects: 584
Study 29355055 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment monitoring and adjustment of procedures
Number of subjects: 584
Study 27271718 — intervention group
Group type: EXPERIMENTAL
Intervention: LA‐TME
Number of subjects: 45
Study 27271718 — intervention group
Group type: COMPARATOR
Intervention: TA‐TME
Number of subjects: 45
Study 24673051 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut implantation
Number of subjects: 110
Study 24673051 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 110
Study 22307524 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-dispersible hesperetin, 150 mg single dose
Number of subjects: 0
Study 20813872 — intervention group
Group type: EXPERIMENTAL
Intervention: MT MR imaging in HD gene carriers
Number of subjects: 30
Study 20813872 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 17912223 — intervention group
Group type: EXPERIMENTAL
Intervention: Convective dialytic therapies (hemodiafiltration)
Number of subjects: 0
Study 17912223 — intervention group
Group type: COMPARATOR
Intervention: Diffusive techniques (hemodialysis)
Number of subjects: 0
Study 16262543 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions with detailed action plans and barrier-focused mental strategies
Number of subjects: 240
Study 16262543 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions with a weekly diary kept for 6 weeks
Number of subjects: 240
Study 16262543 — intervention group
Group type: COMPARATOR
Intervention: Standard care rehabilitation program
Number of subjects: 240
Study 12011290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Delta(9)-Tetrahydrocannabinol (THC)
Number of subjects: 16
Study 12011290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis sativa plant extract
Number of subjects: 16
Study 12011290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10450481 — intervention group
Group type: EXPERIMENTAL
Intervention: Five second stretching group (holding each stretch for 5 seconds, 9 times, total 45 seconds per exercise)
Number of subjects: 24
Study 10450481 — intervention group
Group type: EXPERIMENTAL
Intervention: Fifteen second stretching group (holding each stretch for 15 seconds, 3 times, total 45 seconds per exercise)
Number of subjects: 24
Study 10450481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 24
Study 10450481 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between treatment groups
Number of subjects: 24
Study 7788007 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) treatment for a period of 2.8 (2.8) years with a mean daily dose of 77 (18) micrograms/m2
Number of subjects: 16
Study 7788007 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) treatment
Number of subjects: 16
Study 28426515 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA for 20 minutes targeting the motor cortex bilaterally)
Number of subjects: 10
Study 28426515 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS (2 mA for 20 minutes targeting the motor cortex bilaterally)
Number of subjects: 10
Study 28426515 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (2 mA for 20 minutes targeting the motor cortex bilaterally)
Number of subjects: 10
Study 30664020 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical fecal stream diversion
Number of subjects: 28
Study 30664020 — intervention group
Group type: COMPARATOR
Intervention: Rectal samples
Number of subjects: 28
Study 29031121 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlimited access to BRECONDA with usual care
Number of subjects: 64
Study 29031121 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study 27062800 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue
Number of subjects: 349
Study 27062800 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene
Number of subjects: 349
Study 23427865 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion rate of 0.01 mL/min
Number of subjects: 24
Study 23427865 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion rate of 0.05 mL/min
Number of subjects: 24
Study 23427865 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion rate of 0.1 mL/min
Number of subjects: 24
Study 23427865 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion rate of 0.5 mL/min
Number of subjects: 24
Study 21378358 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB plus ALNS (Group B)
Number of subjects: 112
Study 21378358 — intervention group
Group type: COMPARATOR
Intervention: SLNB alone (Group A)
Number of subjects: 112
Study 21378358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 19397849 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1.25-5.0 mg daily)
Number of subjects: 86
Study 19397849 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-2.0 mg daily)
Number of subjects: 86
Study 19397849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17504683 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid for six months (6H)
Number of subjects: 316
Study 17504683 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin and isoniazid for three months (3RH)
Number of subjects: 316
Study 17504683 — intervention group
Group type: COMPARATOR
Intervention: Rifampin and pyrazinamide for two months (2RZ)
Number of subjects: 316
Study 15244235 — intervention group
Group type: EXPERIMENTAL
Intervention: Likert scale
Number of subjects: 120
Study 15244235 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric VAS
Number of subjects: 120
Study 15244235 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple VAS
Number of subjects: 120
Study 15244235 — intervention group
Group type: COMPARATOR
Intervention: All response options
Number of subjects: 120
Study 11551130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimens concurrent with radiation therapy
Number of subjects: 0
Study 11551130 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-compatible applicators for intracavitary radiation, CT simulation, and three-dimensional treatment planning for EBRT
Number of subjects: 0
Study 9674079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 34
Study 9674079 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched patients who did not commit suicide)
Number of subjects: 34
Study 8011000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorohydrocarbons-free glyceryl trinitrate pump spray with low ethanol content (TL)
Number of subjects: 0
Study 8011000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorocarbon-free GTN pump spray with high ethanol content (TH)
Number of subjects: 0
Study 8011000 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluorocarbon-containing GTN spray (R)
Number of subjects: 0
Study 8011000 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray (TL-matched placebo)
Number of subjects: 0
Study 2910090 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of vancomycin orally four times daily for an average of 10 days
Number of subjects: 46
Study 2910090 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of vancomycin orally four times daily for an average of 10 days
Number of subjects: 46
Study 376236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Heparin therapy
Number of subjects: 35
Study 376236 — intervention group
Group type: EXPERIMENTAL
Intervention: Trasylol
Number of subjects: 35
Study 376236 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who died)
Number of subjects: 35
Study 31816306 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient ibuprofen plus acetaminophen (nonopioid, n=85)
Number of subjects: 170
Study 31816306 — intervention group
Group type: COMPARATOR
Intervention: Outpatient ibuprofen plus hydrocodone‐acetaminophen (opioid, n=85)
Number of subjects: 170
Study 30640303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-load resistance training (LL; n = 14, loads for 30-35 repetitions)
Number of subjects: 32
Study 30640303 — intervention group
Group type: COMPARATOR
Intervention: Higher-load resistance training (HL; n = 18, loads for 8-10 repetitions)
Number of subjects: 32
Study 30640303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-load resistance training (LL)
Number of subjects: 32
Study 30640303 — intervention group
Group type: COMPARATOR
Intervention: Higher-load resistance training (HL)
Number of subjects: 32
Study 28824041 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg/day
Number of subjects: 30
Study 28824041 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg/day + Teneligliptin 20 mg/day
Number of subjects: 30
Study 25217230 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy in primary therapy of PCNSL
Number of subjects: 526
Study 23725788 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone sleeping position
Number of subjects: 10
Study 23725788 — intervention group
Group type: COMPARATOR
Intervention: Supine sleeping position
Number of subjects: 10
Study 21343556 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg (subcutaneous, monthly)
Number of subjects: 1776
Study 21343556 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg (intravenous, dose adjusted for renal impairment)
Number of subjects: 1776
Study 18302468 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachments only (AO)
Number of subjects: 31
Study 18302468 — intervention group
Group type: EXPERIMENTAL
Intervention: Interproximal reduction only (IO)
Number of subjects: 31
Study 18302468 — intervention group
Group type: COMPARATOR
Intervention: Neither attachments nor interproximal reduction (N)
Number of subjects: 31
Study 16236778 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapting RA afferent fibers
Number of subjects: 0
Study 16236778 — intervention group
Group type: COMPARATOR
Intervention: Static or vibrating gratings with varying spatial period and vibratory frequency
Number of subjects: 0
Study 15057391 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching with 36% phosphoric acid gel - Conditioner 36 (Dentsply) for 20 s, followed by water rinse for 15 s
Number of subjects: 10
Study 15057391 — intervention group
Group type: COMPARATOR
Intervention: Etching with NRC - Non Rinse Conditioner (Dentsply) for 20 s, followed by air drying for 15 s
Number of subjects: 10
Study 10711472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent compression pump
Number of subjects: 16
Study 10711472 — intervention group
Group type: COMPARATOR
Intervention: Compression bandages
Number of subjects: 16
Study 9176034 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (200 mg zinc sulphate, 500 mg ascorbic acid, 600 mg alpha-tocopherol, 30 mg beta-carotene daily for 8 weeks)
Number of subjects: 40
Study 9176034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 weeks)
Number of subjects: 40
Study 9176034 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 40
Study 1376842 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (1.25-2.5 mg twice daily)
Number of subjects: 28
Study 1376842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2858421 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol (0.28 mg/kg)
Number of subjects: 0
Study 2858421 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (0.1 mg/kg)
Number of subjects: 0
Study 2858421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31318863 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment with a locking plate
Number of subjects: 88
Study 31318863 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 88
Study 29743380 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT plus 14-day cilostazol (Carrier/DAPT+Cilostazol)
Number of subjects: 128
Study 29743380 — intervention group
Group type: COMPARATOR
Intervention: DAPT (Carrier/DAPT)
Number of subjects: 128
Study 29743380 — intervention group
Group type: COMPARATOR
Intervention: DAPT (Noncarrier/DAPT)
Number of subjects: 128
Study 29743380 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of cilostazol
Number of subjects: 128
Study 29743380 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrier/DAPT+Cilostazol
Number of subjects: 128
Study 29743380 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of cilostazol
Number of subjects: 128
Study 26692120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 26692120 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 25113414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 50
Study 25113414 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate
Number of subjects: 50
Study 22670598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg every 6 h)
Number of subjects: 9
Study 22670598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 9
Study 22670598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 20492655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus simvastatin 20 mg (EZ + simva 10/20 mg)
Number of subjects: 93
Study 20492655 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 93
Study 19167588 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe + pravastatin 10 to 40 mg/d
Number of subjects: 795
Study 19167588 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe + simvastatin 10 to 80 mg/d
Number of subjects: 795
Study 19167588 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe + pravastatin
Number of subjects: 795
Study 19167588 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe + simvastatin
Number of subjects: 795
Study 15278749 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day) for 12 months
Number of subjects: 80
Study 12365905 — intervention group
Group type: COMPARATOR
Intervention: Optisol-GS
Number of subjects: 90
Study 12365905 — intervention group
Group type: COMPARATOR
Intervention: Chen Medium (CM)
Number of subjects: 90
Study 9722253 — intervention group
Group type: EXPERIMENTAL
Intervention: MM + MNF (multi-nutrient fortification of mother's milk)
Number of subjects: 0
Study 9722253 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MM (breastfeeding after mother's milk)
Number of subjects: 0
Study 9722253 — intervention group
Group type: COMPARATOR
Intervention: Post-FF (formula feeding after hospital discharge)
Number of subjects: 0
Study 7863047 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Oxygen Therapy (CAOT) - Group B
Number of subjects: 58
Study 7863047 — intervention group
Group type: COMPARATOR
Intervention: No Continuous Ambulatory Oxygen Therapy (CAOT) - Group A
Number of subjects: 58
Study 7863047 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group B and Group A
Number of subjects: 58